Idiopathic thrombocytopenic purpura (ITP) care at Mayo Clinic

Your Mayo Clinic care team. Your multidisciplinary team of experts will include hematology doctors, pathologists who specialize in diseases of the blood and blood cells (hematopathologists), and other specialists as needed. They collaborate to provide coordinated care.

Advanced diagnosis and treatment. Mayo Clinic doctors have deep experience in diagnosing ITP, which takes expertise in distinguishing it from thrombocytopenia caused by underlying illness or medications. They also use a range of treatment options and research potential future treatments.

Expertise and rankings

Mayo Clinic's idiopathic thrombocytopenic purpura (ITP) experts provide comprehensive care for more than 600 adults and children with ITP each year.

  • Experience. You'll benefit from the expertise of Mayo Clinic's skilled hematologists, who have significant experience in diagnosing and treating ITP.
  • Newest technology and research. Mayo doctors use the latest technology and are involved in research to improve treatment for ITP. At Mayo Clinic, you may have access to ongoing clinical trials and new treatments for ITP.

Locations, travel and lodging

Mayo Clinic has major campuses in Phoenix and Scottsdale, Arizona; Jacksonville, Florida; and Rochester, Minnesota. The Mayo Clinic Health System has dozens of locations in several states.

For more information on visiting Mayo Clinic, choose your location below:

Costs and insurance

Mayo Clinic works with hundreds of insurance companies and is an in-network provider for millions of people.

In most cases, Mayo Clinic doesn't require a physician referral. Some insurers require referrals, or may have additional requirements for certain medical care. All appointments are prioritized on the basis of medical need.

Learn more about appointments at Mayo Clinic.

Please contact your insurance company to verify medical coverage and to obtain any needed authorization prior to your visit. Often, your insurer's customer service number is printed on the back of your insurance card.

Aug. 09, 2017
References
  1. AskMayoExpert. Immune thrombocytopenia (ITP). Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2015.
  2. AskMayoExpert. Spleen disorders and splenectomy. Rochester, Minn.: Mayo Foundation for Medical Education and Research; 2014.
  3. Immune thrombocytopenia (ITP). Merck Manual Professional Version. http://www.merckmanuals.com/professional/hematology-and-oncology/thrombocytopenia-and-platelet-dysfunction/immune-thrombocytopenia-(itp). Accessed Feb. 10, 2016.
  4. Yeo CJ, et al., eds. Splenectomy for conditions other than trauma. In: Shackelford's Surgery of the Alimentary Tract. 7th ed. Philadelphia, Pa.: Elsevier Saunders; 2013.
  5. Immune thrombocytopenic? National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/itp. Accessed Feb. 9, 2016.
  6. George JN, et al. Immune thrombocytopenia (ITP) in adults: Clinical manifestations and diagnosis. http://www.uptodate.com/home. Accessed Feb. 10, 2016.
  7. Riggin EA. Allscripts EPSi. Mayo Clinic, Rochester, Minn. Feb. 11, 2016.
  8. Neunert C, et al. The American Society of Hematology 2011 evidence-based guidelines for immune thrombocytopenia. Blood. 2011;117:4190.
  9. CBC with differential, blood. Mayo Medical Laboratories. http://www.mayomedicallaboratories.com/test-catalog/Clinical+and+Interpretive/9109. Accessed Feb. 12, 2016.
  10. George JN, et al. Approach to the adult with unexplained thrombocytopenia. http://www.uptodate.com/home. Accessed Feb. 11, 2016.
  11. George JN, et al. Immune thrombocytopenia (ITP) in adults: Initial treatment and prognosis. http://www.uptodate.com/home. Accessed Feb. 10, 2016.
  12. George JN, et al. Immune thrombocytopenia (ITP) in adults: Second-line and subsequent therapies. http://www.uptodate.com/home. Accessed Feb. 10, 2016.
  13. Leandro MJ. Rituximab and other B cell targeted therapies for rheumatoid arthritis. http://www.uptodate.com/home. Accessed Feb. 16, 2016.
  14. Imuran (azathioprine). U.S. Food and Drug Administration. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/016324s037,017391s016lbl.pdf. Accessed Feb. 16, 2016.
  15. Arnold DM. Positioning new treatments in the management of immune thrombocytopenia. Pediatric Blood & Cancer. 2013;60:S19.
  16. Mesa RA (expert opinion). Mayo Clinic, Scottsdale/Phoenix, Ariz. Feb. 17, 2016.